Free Trial

PharmaCyte Biotech (PMCB) Institutional Ownership

PharmaCyte Biotech logo
$1.81
-0.06 (-3.21%)
(As of 10/31/2024 ET)

Institutional Ownership Changes (13F Filings) for PharmaCyte Biotech (NASDAQ:PMCB)

Current
Institutional Ownership
Percentage
34.24%
Number of
Institutional Buyers
(last 12 months)
2
Total
Institutional Inflows
(last 12 months)
$576.78K
Number of
Institutional Sellers
(last 12 months)
0
Get PMCB Insider Trade Alerts

Want to know when executives and insiders are buying or selling PharmaCyte Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

PMCB Institutional Buying and Selling by Quarter

PharmaCyte Biotech Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2024K2 Principal Fund L.P.327,503$776K0.1%+7.5%3.876%
2/14/2024K2 Principal Fund L.P.304,613$655K0.1%+17.8%3.534%
11/15/2023Sabby Management LLC97,124$204K0.1%N/A1.106%
11/13/2023K2 Principal Fund L.P.258,481$543K0.1%+67.6%2.944%
10/17/2023Equitec Proprietary Markets LLC82,727$174K0.0%+34.7%0.942%
8/15/2023K2 Principal Fund L.P.154,232$441K0.1%-78.7%1.757%
8/14/2023CSS LLC IL13,186$38K0.0%N/A0.150%
7/12/2023Equitec Proprietary Markets LLC61,415$176K0.1%-81.4%0.366%
5/11/2023K2 Principal Fund L.P.723,271$2.06M0.3%-1.2%4.146%
2/10/2023K2 Principal Fund L.P.732,105$2.15M0.3%+19.8%3.909%
1/10/2023FNY Investment Advisers LLC31,100$90K0.1%N/A0.166%
10/26/2022 IQ EQ FUND MANAGEMENT IRELAND Ltd38,771$93K0.0%N/A0.187%
10/11/2022Equitec Proprietary Markets LLC330,694$794K0.2%-3.6%1.594%
10/4/2022Csenge Advisory Group200,104$480K0.0%N/A0.964%
7/18/2022Equitec Proprietary Markets LLC342,994$768K0.2%+10.9%1.655%
5/17/2022Shay Capital LLC944,666$2.17M0.3%+42.6%4.559%
4/25/2022FNY Investment Advisers LLC59,066$135K0.1%N/A0.285%
4/22/2022Equitec Proprietary Markets LLC309,294$711K0.2%+19.6%1.493%
2/15/2022Shay Capital LLC662,337$1.66M0.3%+4,434.7%3.197%
1/31/2022Equitec Proprietary Markets LLC258,694$647K0.1%N/A1.249%
11/16/2021Schonfeld Strategic Advisors LLC88,200$280K0.0%N/A0.426%
11/12/2021 NorthRock Partners LLC37,164$118K0.0%N/A0.179%
(Data available from 1/1/2016 forward)

PMCB Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of PMCB shares?

During the previous two years, the following institutional investors and hedge funds held shares of PharmaCyte Biotech shares: K2 Principal Fund L.P. ($776K), Sabby Management LLC ($204K), Equitec Proprietary Markets LLC ($174K), and FNY Investment Advisers LLC ($90K), CSS LLC IL ($38K).Learn more on PMCB's institutional investors.

What percentage of PharmaCyte Biotech stock is owned by institutional investors?

34.24% of PharmaCyte Biotech stock is owned by institutional investors. Learn more on PMCB's institutional investor holdings.

Which institutional investors have been buying PharmaCyte Biotech stock?

The following institutional investors have purchased PharmaCyte Biotech stock in the last 24 months: K2 Principal Fund L.P. ($294.21K), Sabby Management LLC ($97.12K), FNY Investment Advisers LLC ($31.10K), Equitec Proprietary Markets LLC ($21.31K), and CSS LLC IL ($13.19K).

How much institutional buying is happening at PharmaCyte Biotech?

Institutional investors have bought a total of 456,935 shares in the last 24 months. This purchase volume represents approximately $1.10M in transactions.

Which PharmaCyte Biotech major shareholders have been selling company stock?

The following institutional investors have sold PharmaCyte Biotech stock in the last 24 months: K2 Principal Fund L.P. ($577.87K), and Equitec Proprietary Markets LLC ($269.28K).

How much institutional selling is happening at PharmaCyte Biotech?

Institutional investors have sold a total of 847,152 shares in the last 24 months. This volume of shares sold represents approximately $2.42M in transactions.



This page (NASDAQ:PMCB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners